Woodline Partners’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
Other funds holding DNLI
Woodline Partners's DNLI Position: Q2 2026 in Review
Woodline Partners held its Denali Therapeutics (DNLI) position steady in Q2 2026 at 364,082 shares worth $9.36M. The position accounts for 0.03% of the portfolio, ranked #551.
Woodline Partners first reported a position in DNLI in Q4 2021 and has held it in 17 quarters since. The position peaked at $17.6M in Q3 2023. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.
- Woodline Partners held 364,082 shares of Denali Therapeutics worth $9.36M as of Q2 2026.
- Woodline Partners left its Denali Therapeutics share count unchanged in Q2 2026.
- Denali Therapeutics made up 0.03% of Woodline Partners's portfolio in Q2 2026, its #551 holding.
- Woodline Partners first reported a position in Denali Therapeutics in Q4 2021 and has held it in 17 quarters since.
- Woodline Partners's Denali Therapeutics position peaked at $17.6M in Q3 2023.
- 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.
Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.